Josh Armenia on Impact of Mutated Gene Analysis in Prostate Cancer
Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the impact of a gene mutation analysis study in prostate cancer.
This study was a mutational significance analysis, conducted to detect novel genes and pathways in 918 patients with prostate cancer. Twenty-three novel genes were identified as a result.
Due to the large cohort, defining biomarkers in advanced disease are possible, says Armenia.
By comparing the genomic alternation across Gleason scores, markers of risk progression of advanced disease within primary tumors should also be a realistic opportunity.